Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fimasartan/hydrochlorothiazide - Boryung Pharmaceutical

Next Previous
Search
Drug Profile

Fimasartan/hydrochlorothiazide - Boryung Pharmaceutical

Alternative Names: BKE-001; BR 1011; Diarakhor; Kanarb plus

Latest Information Update: 21 Oct 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boryung Pharmaceutical
  • Developer Boryung Pharmaceutical; Stendhal Mexico
  • Class Antihypertensives; Benzodiazepines; Pyrimidinones; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Essential hypertension

Most Recent Events

  • 21 Oct 2020 Fimasartan/hydrochlorothiazide is still in phase III for Essential hypertension (In the elderly) in South Korea (PO) (NCT03246555)
  • 09 Dec 2019 Boryung Pharmaceutical completes the phase III FITNESS trial in Essential hypertension (In the elderly) in South Korea (PO) (NCT03246555)
  • 07 Aug 2017 Phase-III clinical trials in Essential hypertension (In the elderly) in South Korea (PO) (NCT03246555)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top